NECTIN4 and neoplasm: Promising results have been found for the combination of pembrolizumab with an antibody–drug conjugate (enfortumab vedotin) targeting tumor-expressed nectin-4 with an antibody to release the antimicrotubule agent auristatin-E for tumor cell destruction [86].